The Retatrutide File

What Is Retatrutide?

Retatrutide (internal designation: LY3437943) is a once-weekly injectable peptide developed by Eli Lilly and Company. It is currently in Phase III clinical development and has not been approved by the FDA or any other regulatory agency. What makes it structurally distinct from every other agent in the GLP-1 drug class is its triple receptor activity: it simultaneously activates the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.

Semaglutide (the active ingredient in Ozempic and Wegovy) is a GLP-1 single agonist. Tirzepatide (Mounjaro, Zepbound) is a GLP-1/GIP dual agonist. Retatrutide adds a third axis: glucagon receptor agonism. Each additional receptor pathway contributes distinct physiological effects, and the combination appears to produce synergistic results that significantly exceed what either single or dual agonism can achieve.

The primary evidence comes from the TRIUMPH Phase III programme: seven trials enrolling 5,800+ participants across multiple countries, covering obesity, type 2 diabetes, metabolic liver disease, and cardiovascular disease. The headline number from TRIUMPH-4, the pivotal obesity trial: 28.7% mean body weight reduction at the 12mg dose over 68 weeks in adults with obesity but without type 2 diabetes. No drug has achieved a comparable result in a randomised, double-blind, placebo-controlled trial of that scale.

For context: semaglutide 2.4mg (Wegovy) achieves approximately 15% mean body weight reduction over 68 weeks in the same population (STEP 1 trial); tirzepatide 15mg (Zepbound) achieves approximately 21 to 22% (SURMOUNT-1). Retatrutide at 12mg represents a roughly 37% improvement in efficacy over tirzepatide and an 86% improvement over semaglutide at their respective highest approved doses — a genuine step-change in the efficacy ceiling of pharmacological weight management.

Eli Lilly has indicated that NDA submission is expected in late 2026 or early 2027. If approved, retatrutide would enter a market already dominated by Lilly's own tirzepatide and Novo Nordisk's semaglutide, effectively superseding tirzepatide in the highest-efficacy segment and positioning Lilly at the leading edge of the next generation of metabolic pharmacotherapy.

How Retatrutide Works: The Triple Agonist Mechanism

Retatrutide's mechanism can be understood as three layered systems working simultaneously. Each targets distinct physiological pathways; together they converge on weight loss through mechanisms that are largely independent and therefore additive.

The GLP-1 Receptor

GLP-1 receptor agonism is the pharmacological foundation of the modern obesity drug class. When retatrutide activates GLP-1 receptors in the hypothalamus, it reduces appetite and increases satiety signalling. In the gut, GLP-1 receptor activation slows gastric emptying. In the pancreas, GLP-1 agonism stimulates glucose-dependent insulin secretion without causing hypoglycaemia when glucose is normal.

The GIP Receptor

GIP receptor agonism was first introduced to obesity pharmacotherapy via tirzepatide. It appears to enhance the appetite-suppressive signal while simultaneously reducing the nausea and GI side effects that GLP-1 agonism alone tends to produce — producing a net pharmacodynamic improvement over GLP-1 monotherapy.

The Glucagon Receptor — The Key Differentiator

The most significant pharmacological distinction between retatrutide and every prior agent is glucagon receptor agonism. In the context of simultaneous GLP-1 agonism, the GLP-1 component's insulin-stimulating effect offsets the glucagon-induced glycaemic rise. The glucagon receptor is expressed in tissues beyond the pancreas, and it is those peripheral effects that drive the additional efficacy.

• Liver (hepatic lipid oxidation)Glucagon receptor activation directly increases the rate at which liver cells burn fat for energy. This is the primary mechanism behind retatrutide’s 86% relative liver fat reduction in Phase 2 data.
• Adipose tissue (thermogenesis)Glucagon receptor agonism increases thermogenesis and energy expenditure, effectively raising the resting metabolic rate — additive to the caloric restriction driven by GLP-1-mediated appetite suppression.
• Central nervous system (appetite suppression)Glucagon receptors in the hypothalamus and brain stem appear to independently reinforce appetite suppression, additive to the GLP-1 signal.

For a detailed pharmacological breakdown of all three receptor axes, see the dedicated mechanism article.

The TRIUMPH Trial Programme

TRIUMPH is the Phase III clinical development programme for retatrutide: seven individual trials, 5,800+ participants enrolled across multiple countries, covering obesity, type 2 diabetes, cardiovascular disease, metabolic liver disease, and obstructive sleep apnoea.

For full trial-by-trial data and endpoint analysis, see the clinical trial results article.

Weight Loss: What the Data Shows

The 28.7% figure from TRIUMPH-4 is the headline. The complete picture requires the dose-response relationship, the responder analysis across weight loss thresholds, and the trajectory over the 68-week trial period.

Dose-Response Relationship

TRIUMPH-4 evaluated three active doses versus placebo. All three active doses demonstrated statistically significant and clinically meaningful weight loss; the dose-response relationship was clear and monotonic.

Responder Analysis at 12mg

Mean weight loss figures can obscure the distribution of responses. Responder analysis provides a more clinically meaningful picture for patient counselling.

• ≥5% body weight reduction~95% of participants
• ≥10% body weight reduction~90% of participants
• ≥15% body weight reduction~85% of participants
• ≥20% body weight reduction~75% of participants
• ≥25% body weight reduction~55% of participants

For comparison: in STEP 1 (semaglutide), approximately 69% achieved ≥10% weight loss; in SURMOUNT-1 (tirzepatide 15mg), approximately 91%. Retatrutide at 12mg approaches a ceiling of response not previously observed in pharmacological weight management.

Weight Loss Trajectory and Plateau

TRIUMPH-4 participants on 12mg continued to show weight reduction at the 68-week endpoint without an apparent plateau, suggesting that 68 weeks may not represent the maximum achievable effect.

Body Composition

Retatrutide's body composition data from TRIUMPH-4 showed fat mass loss predominating, consistent with the class. The glucagon receptor-mediated increase in energy expenditure may theoretically help preserve metabolic rate during caloric restriction, but this requires confirmation from longer-term follow-up data. For a detailed breakdown, see the weight loss projections article.

Liver Fat and Metabolic Benefits

Beyond the weight loss data, retatrutide's most striking single finding is an 86% relative reduction in liver fat content measured by MRI-PDFF in Phase 2 data, published in Nature Medicine. This was the largest liver fat reduction ever recorded for any pharmaceutical compound in a controlled clinical trial at the time of publication.

The mechanism is directly attributable to glucagon receptor agonism in the liver. When retatrutide activates glucagon receptors in hepatocytes, it directly stimulates hepatic fatty acid oxidation. This hepatic fat-burning effect is independent of and additive to the secondary liver fat reduction that would be expected from overall caloric restriction and weight loss alone.

The clinical implications extend well beyond obesity management. Approximately 25% of the global adult population has metabolic dysfunction-associated steatotic liver disease (MASLD). TRIUMPH-6 was designed specifically for MASH, using liver biopsy-confirmed histological endpoints to meet the regulatory bar for a dedicated MASH indication.

• ALT and ASTLiver enzymes normalised or significantly reduced in participants with elevated baseline values.
• HOMA-IRA validated measure of insulin resistance. Improved substantially at all doses, reflecting improved peripheral glucose metabolism independent of weight loss alone.
• Fasting triglyceridesReduced substantially, consistent with both the weight loss component and direct hepatic lipid metabolism effects of glucagon receptor agonism.
• AdiponectinAn insulin-sensitising adipokine that is paradoxically suppressed in obesity. Increased with retatrutide treatment — an independent marker of improved metabolic phenotype.

Side Effects and Safety Profile

Retatrutide's safety profile has two components: the class-typical gastrointestinal events shared with all GLP-1 receptor agonists, and a novel adverse event (dysesthesia) that appears specific to glucagon receptor agonism.

Gastrointestinal Side Effects

The most commonly reported adverse events in TRIUMPH-4 were gastrointestinal: nausea, diarrhoea, vomiting, and constipation. GI events occurred primarily during the dose-escalation phase and largely resolved or reduced in intensity once the maintenance dose was reached.

Dysesthesia — The Novel Signal

The most clinically distinctive adverse event in retatrutide's profile is dysesthesia: abnormal, often unpleasant skin sensations including tingling, burning, numbness, crawling, or electric feelings, primarily in the extremities.

At the 12mg dose in TRIUMPH-4, dysesthesia was reported by approximately 20.9% of participants. At 8mg the rate was lower; at 4mg, lower still — a clear dose-dependent relationship that strongly suggests the effect is pharmacodynamic rather than idiosyncratic.

Other Safety Signals

• Heart rateA modest resting heart rate increase (2 to 4 bpm) is a class-wide effect of GLP-1 receptor agonism. Observed with retatrutide at rates consistent with the class.
• Gallbladder eventsRapid, substantial weight loss increases the risk of cholelithiasis (gallstone formation). Observed at rates broadly consistent with other GLP-1 agents.
• HypoglycaemiaIn patients without T2D (the TRIUMPH-4 population), hypoglycaemia risk was low and similar to placebo.

For complete side effect incidence rates and management guidance, see the side effects article.

Retatrutide vs Semaglutide and Tirzepatide

Retatrutide enters a market with two established agents. Notably, Eli Lilly itself manufactures tirzepatide (Zepbound/Mounjaro), making this partly an intra-company generational transition.

The key takeaway: retatrutide's efficacy advantage is substantial and mechanistically justified. The trade-off is dysesthesia, a novel adverse event at 20.9% at 12mg with no analogue in the existing class.

See the dedicated comparison files: Retatrutide vs Semaglutide and Retatrutide vs Tirzepatide.

Dosage and Administration

Retatrutide is administered as a once-weekly subcutaneous injection, the same delivery format as semaglutide and tirzepatide. Phase III used a gradual dose-escalation protocol designed to minimise GI side effects during the adjustment period.

• 4mg weeklyLower bound of efficacy studied. ~17.5% mean weight loss at 68 weeks. Lowest side effect burden including the lowest dysesthesia rate.
• 8mg weeklyMiddle dose. ~22.8% mean weight loss. Intermediate dysesthesia rate. May represent the optimal benefit-risk profile for many patients.
• 12mg weeklyHighest dose studied. 28.7% mean weight loss. Highest efficacy, and the highest dysesthesia rate at approximately 20.9%.

The commercial dosing schedule has not been officially announced by Eli Lilly as of April 2026. See the full dosage guide.

FDA Approval Timeline

As of April 2026, retatrutide remains investigational. Based on Eli Lilly's public guidance, NDA submission is expected in late 2026 or early 2027.

For detailed regulatory pathway analysis and PDUFA projections, see the FDA approval article.

Who Will Qualify?

Based on precedent from the semaglutide (Wegovy) and tirzepatide (Zepbound) labels, retatrutide's obesity indication will likely cover:

• ·Adults with a BMI of ≥30 kg/m² (obesity class I or higher)
• ·Adults with a BMI of ≥27 kg/m² plus at least one weight-related comorbidity (hypertension, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease)

Insurance coverage is the dominant real-world access variable. The GLP-1 class has faced persistent payer resistance for the obesity indication specifically. Retatrutide will face the same structural barrier, and access will depend heavily on commercial pricing and formulary negotiations following approval.

What We Don't Yet Know

• Cardiovascular outcomes (TRIUMPH-3)

  Whether retatrutide reduces MACE in high-risk patients is critical for broad label expansion. TRIUMPH-3 is ongoing and represents the most consequential missing data.

• Full dysesthesia characterisation

  Mechanism confirmation, predictive risk factors, reversibility on dose reduction or discontinuation, and long-term course.

• TRIUMPH-2 T2D results

  Full T2D data from the second dedicated diabetes trial. Pending publication and expected to contribute to the NDA filing.

• TRIUMPH-6 MASH histology

  Whether the 86% liver fat reduction from Phase 2 translates into MASH resolution and fibrosis regression on biopsy.

• Optimal maintenance dose strategy

  Whether patients who achieve target weight loss at 8mg need to maintain 12mg for durability, or whether a lower maintenance dose preserves the effect.

• Obstructive sleep apnoea outcomes (TRIUMPH-7)

  Following tirzepatide’s precedent in SURMOUNT-OSA, results from TRIUMPH-7 could support a dedicated OSA indication.

• Pricing and insurance coverage

  List price, net price after rebates, and formulary positioning relative to tirzepatide and semaglutide.

• Drug-drug interactions in polypharmacy

  Real-world patients with obesity and T2D are typically on multiple medications. The DDI profile in complex polypharmacy scenarios remains less characterised.

Frequently Asked Questions